Everolimus Tablets (0.25 mg / 0.5 mg / 0.75 mg / 5 mg / 10 mg)

Healthy Inc is a specialized global supplier and exporter of advanced high-containment oncology, transplant immunology, and targeted mTOR-inhibitor therapeutics. We provide ultra-high-purity, kinetically precise Everolimus Tablets, manufactured in WHO–GMP certified, strictly segregated high-containment (OEB 4) oral solid dosage facilities. This “Mammalian Target of Rapamycin (mTOR) Inhibitor” is a massive-volume, incredibly high-value export to organ transplant centers, advanced thoracic and renal oncology networks, and government health ministries in LATAM, the CIS, Africa, and Southeast Asia, serving as both a life-saving prophylactic against kidney/liver rejection and a frontline targeted therapy for advanced Renal Cell Carcinoma and HR-Positive Breast Cancer.

Product Overview

This highly advanced formulation operates as a master biochemical switch inside the human cell. By targeting the mTOR protein, it dictates whether a cell is allowed to divide, grow, and consume nutrients. In a transplant patient, it stops immune cells from multiplying. In a cancer patient, it literally starves the tumor to death.

The “mTOR Blockade & Angiogenesis Inhibitor” Specialist:

• Mechanism 1 (The Oncological Starvation – Macro-Dose): In advanced cancers, the mTOR pathway is hyperactive, constantly telling the tumor to grow and build new blood vessels. Everolimus binds to an intracellular protein (FKBP-12) to form an inhibitory complex that violently binds to and blocks mTORC1. This instantly shuts down the translation of genes required for the tumor cell to divide, while simultaneously crashing the production of VEGF (Vascular Endothelial Growth Factor), choking off the tumor’s blood supply.
• Mechanism 2 (The Transplant Immunosuppressor – Micro-Dose): Following a kidney or liver transplant, the body’s T-cells detect the foreign organ and attempt to destroy it. T-cell proliferation is driven by Interleukin-2 (IL-2). Everolimus blocks the mTOR pathway inside the T-cells, leaving them completely “deaf” to the IL-2 signal. The T-cells cannot multiply, halting the organ rejection process without the severe nephrotoxicity (kidney damage) associated with older immunosuppressants.
• The “Dual-Market” Matrix: Everolimus is unique in that its clinical application changes entirely based on the dose. The 0.25 mg to 0.75 mg variants supply the massive, continuous global demand for lifelong transplant maintenance. The 5 mg and 10 mg variants supply the ultra-high-value oncology sector, offering a lifeline when standard chemotherapies fail.

Product Composition & Strength

We supply this product as a Precision-Blended, Antioxidant-Stabilized Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical survival of the highly oxidative, potent API.

*Pack Sizes: 10×10 Alu-Alu Blisters (Transplant) or 3×10 Alu-Alu Blisters (Oncology – 30 Day Supply).

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers, Oncology/Transplant Distributors, and Hospital Procurement Boards.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• OEB 4 High-Containment & Narrow Therapeutic Index Control (CRITICAL COMPLIANCE): Everolimus is a highly potent cytotoxic and immunosuppressive agent. Manufacturing this compound in standard generic facilities is strictly prohibited due to severe cross-contamination risks. Our production occurs in dedicated High-Containment Blocks (OEB 4) utilizing closed-loop systems. Because the therapeutic blood level for transplant patients is a razor-thin 3 to 8 ng/mL, our suites utilize elite geometric dilution and intensive HPLC testing to guarantee absolute Content Uniformity. A 10% deviation in a 0.25mg tablet could cost a patient their new kidney—we guarantee clinical perfection.

Therapeutic Indications (Human Use)

Indicated for the targeted, highly specialized management of organ rejection and severe malignancies:

• Organ Transplant Prophylaxis: Prevention of organ rejection in adult patients at low to moderate immunological risk receiving a kidney or liver transplant (used concurrently with microemulsion Cyclosporine or Tacrolimus and corticosteroids).
• Advanced Renal Cell Carcinoma (RCC): Treatment of advanced RCC in adults whose disease has progressed on or after treatment with VEGF-targeted therapy.
• Breast Cancer: Treatment of postmenopausal women with advanced HR-positive, HER2-negative breast cancer (in combination with Exemestane).
• Neuroendocrine Tumors (NET): Treatment of progressive neuroendocrine tumors of pancreatic, gastrointestinal, or lung origin.

Dosage & Administration

Recommended Dosage (Strictly as per Transplant/Oncology Guidelines):

• Transplant: Typically 0.75 mg twice daily, strictly titrated based on therapeutic drug monitoring (blood trough levels).
• Oncology: Typically 10 mg once daily.
• Administration (The Consistency Rule): Must be taken consistently either always with food or always without food. Mixing the two methods causes massive, unpredictable swings in blood absorption. Tablets must be swallowed whole with a glass of water.

Safety Warnings (CRITICAL Regulatory & Clinical Data):

• BLACK BOX WARNING (Immunosuppression & Malignancies): Everolimus profoundly suppresses the immune system, leaving the patient highly susceptible to fatal opportunistic infections (bacterial, viral, fungal) and the development of secondary lymphomas or skin cancers.
• Non-Infectious Pneumonitis (FATAL WARNING): A severe, recognized class effect of mTOR inhibitors is the development of non-infectious pneumonitis. If a patient presents with sudden, unexplained hypoxia, cough, or dyspnea, the drug must be interrupted immediately.
• Severe Stomatitis: In oncology dosing, extreme, painful mouth ulcers (stomatitis) occur in a vast majority of patients, often requiring dose reductions or specialized dexamethasone mouthwashes to maintain compliance.
• CYP3A4 & P-gp Interactions: Everolimus is exclusively metabolized by CYP3A4. Co-administration with strong inhibitors (like Ketoconazole or Clarithromycin) will cause fatal drug accumulation. Co-administration with strong inducers (like Rifampin) will crash blood levels and cause organ rejection.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving international Pharma Traders, Wholesalers, and Oncology/Transplant Networks. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Antineoplastics, Immunosuppressants, and OEB 4 High-Containment Formulations. Whether you are looking for a reliable Government Tender Supplier for national transplant programs in the CIS or a B2B Pharma Marketplace partner for Latin America, our highly regulated logistics network ensures timely, secure delivery of WHO-GMP certified products.